Detalles de la búsqueda
1.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs
; 38(5): 1570-1579, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140889
2.
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Invest New Drugs
; 37(1): 118-126, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29995286
3.
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Liver Int
; 39(8): 1468-1477, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30963691
4.
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Br J Cancer
; 119(10): 1208-1214, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30318515
5.
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Int J Mol Sci
; 18(5)2017 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28481241
6.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-ß receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Invest New Drugs
; 33(2): 357-70, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25529192
7.
Defining a therapeutic window for the novel TGF-ß inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
Br J Clin Pharmacol
; 77(5): 796-807, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24868575
8.
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.
Invest New Drugs
; 30(3): 936-49, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21360050
9.
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.
Am J Kidney Dis
; 57(2): 300-3, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21177011
10.
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-ßRI inhibitor galunisertib.
PLoS One
; 16(6): e0253671, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34138968
11.
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-ßRI inhibitor galunisertib.
PLoS One
; 15(3): e0222259, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32210440
12.
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-ß inhibitor galunisertib in patients with pancreatic cancer.
Cancer Chemother Pharmacol
; 84(5): 1003-1015, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31482224
13.
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Clin Cancer Res
; 25(23): 6976-6985, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31481511
14.
TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Cancer Chemother Pharmacol
; 83(5): 975-991, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30887178
15.
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-ß receptor type I inhibitor.
Oncotarget
; 9(6): 6659-6677, 2018 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29467918
16.
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.
Drugs Context
; 5: 212303, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27990167
17.
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Neuro Oncol
; 18(8): 1146-56, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902851
18.
Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.
Drugs Context
; 42015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25834620
19.
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Drug Des Devel Ther
; 9: 4479-99, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26309397
20.
First-in-human dose study of the novel transforming growth factor-ß receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Clin Cancer Res
; 21(3): 553-60, 2015 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25424852